FURIN-HEMMER

European patent · EP3790871 · In force

Register entry

Publication number: EP3790871
Application number: EP19725058
Kind: European patent with effect for Switzerland and Liechtenstein
Status: In force
Specification: Granted
Filed: May 10, 2019
Published: Mar 17, 2021
Granted: Jan 24, 2024
Protection ends at the latest: May 9, 2039
Next annual fee due: May 31, 2027
IPC classes: C07D 401/14 (2006.01)
A61K 31/44 (2006.01)
A61K 31/4427 (2006.01)
C07D 213/76 (2006.01)
C07D 401/04 (2006.01)
C07D 413/12 (2006.01)
Priority: US 201862670050 P 11.05.2018
PCT application: PCT/EP2019/062098 10.05.2019
PCT publication: WO2019/215341 14.11.2019
Filing language: English
Source: Swissreg

What the Federal Institute of Intellectual Property published about this title, newest first.

Jun 1, 2026
Change
Published in Swissreg on 01.06.2026
Nov 7, 2025
Holder’s address changed
Owner
GlaxoSmithKline Intellectual Property Development, Limited, GSK Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, United Kingdom → GlaxoSmithKline Intellectual Property Development, Limited, GSK Medicines Research Centre, Gunnels Wood Road, Stevenage, SG1 2NY, United Kingdom
Published in Swissreg on 07.11.2025
Jun 1, 2025
Change
Published in Swissreg on 01.06.2025
Dec 4, 2024
Change
Published in Swissreg on 04.12.2024
Jun 2, 2024
Change
Published in Swissreg on 02.06.2024
Jan 24, 2024
Granted
Published in Swissreg on 24.01.2024

GSK Medicines Research Centre Gunnels Wood Road, Stevenage, SG1 2NY, GB